Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Paul Hunter, an infectious disease expert at the University of East Anglia, warned about relying too heavily on studies that could just be “random fluke”....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Paul Hunter, professor of medicine at the University of East Anglia, said new infection rates peaked globally in early January and were now back to the level of last October....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...That time Pfizer failed to clinch a deal for AstraZeneca If Ian Read had his way, AstraZeneca would be a unit of US pharma group Pfizer right now....
...That means the iPhone maker has shed $265bn of market value since its peak — more than the entire market capitalisation of Pfizer, Wells Fargo, Procter & Gamble or Chevron....
...asks Ludovic Hunter-Tilney. In music, the big stars still dominate....
...In the US, Allergen confirmed it was in “friendly” talks with Pfizer for a deal that would create the world’s largest drugmaker, with a market cap of over $300bn....
...Allergan So far, Allergan has been a hunter rather than a target in the M&A game....
...Producer: Hunter Hillcoat of Investec. Mogul: Sounds like some kinda jacket Prince Charles would wear for moose shooting. They got moose in London? Yes Man: Sure thing, boss....
...Bargain-hunters have OnePlus’s youth to thank for the price....
...Some analysts and bankers also think Mallinckrodt could turn from hunter to hunted....
...AstraZeneca, which was the subject of a failed £69.4bn bid from Pfizer which would have included a tax inversion, fell 1.6 per cent to £42.75....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...The “v” was added so people searching for them on the internet wouldn’t find themselves confronted by Wikipedia’s entry for “Church (Building)” or Norfolk’s ecclesiastical architecture....
...Ludovic Hunter-Tilney is the FT’s pop critic...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...A study due in mid-2011 on Crestor, AstraZeneca’s biggest seller, may fail to prove that the cholesterol-lowering pill was superior to Pfizer’s Lipitor treatment, Merrill said....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Dystrophy, Hunter syndrome and Fabry and Gaucher disease....
...facilitate an optical V-shaped recovery.”...
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...What do GE, Citigroup, Bank of America, Pfizer and JPMorgan have in common?...
International Edition